Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

US9309324B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Zhuozhi Wang · Millbrae, US
• Junliang Pan · Moraga, US
• Joanna Grudzinska · Cologne, DE
• Christian Votsmeier · Cologne, DE
• Jan Tebbe · Cologne, DE
• Joerg Birkenfeld · Frankfurt am Main, DE
• Nina Wobst · Wuppertal, DE
• Simone Brueckner · Cologne, DE
• Susanne Steinig · Cologne, DE
• Peter Scholz · Cologne, DE

Key dates

• Filing date: Mar 1, 2011
• Grant date: Apr 12, 2016
• Expiry date: Mar 1, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/21
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.